Furthermore, JC63.1C, an anti-CD36 monoclonal antibody, was found to resensitize lapatinib-resistant xenograft tumors to HER2-targeted therapy [231], providing a novel direction for combinatorial treatment strategies in breast cancer. This evidence concerns the gene ERBB2 and breast cancer.